May 31, 2016
The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020. DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Antico...
Read More...
May 12, 2016
Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa. DelveInsight Atrial Fibrillation-Market Insights & Drugs ...
Read More...
Jul 30, 2015
Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA....
Read More...
Aug 27, 2014
DelveInsight is helping worldwide Pharmaceutical companies with its Market Intelligence Reports. VISIT OUR WEBSITE Infectious Diseases and Vaccines The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the development of a fi...
Read More...
Aug 19, 2014
The “ Metastatic Prostate Cancer-Pipeline Insights, 2014”, report by DelveInsight provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides in...
Read More...
Aug 01, 2014
“If a market is growing enormously, you need to understand what’s nourishing it” DelveInsight has launched its Reports under two brands Pharm Delve and Pharm Insights. Pharm Delve reports are known for its extensive detailed information of the Marketed drugs- Global Market, API Market & Manufacturer...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper